Ceftiofur Crystalline Free Acid (Excede)

Ceftiofur crystalline free acid represents an innovative extended-release formulation of ceftiofur, a third-generation cephalosporin antibiotic designed specifically for use in food-producing animals. Marketed under the brand name Excede, this formulation provides sustained therapeutic drug concentrations from a single injection, eliminating the need for multiple daily treatments required by conventional ceftiofur products. This extended-release technology offers significant practical advantages in managing bacterial infections in cattle and swine, reducing animal handling stress, labor requirements, and treatment logistics while maintaining effective antimicrobial therapy against susceptible pathogens.

The mechanism of action of ceftiofur crystalline free acid mirrors that of other beta-lactam antibiotics, involving irreversible binding to penicillin-binding proteins (PBPs) essential for bacterial cell wall synthesis. This binding disrupts the final transpeptidation step in peptidoglycan production, leading to defective cell walls that cannot maintain bacterial structural integrity. The resulting osmotic instability causes cell lysis and rapid bactericidal killing of susceptible organisms. Ceftiofur demonstrates exceptional stability against beta-lactamase enzymes, extending its effective spectrum to include many organisms that would otherwise inactivate the antibiotic through enzymatic degradation.

The extended-release formulation technology distinguishes ceftiofur crystalline free acid from other ceftiofur products. When injected subcutaneously, the crystalline drug creates a depot that slowly releases active medication over an extended period. This depot effect maintains therapeutic blood and tissue concentrations for approximately 7 days following a single dose in cattle, or provides sustained activity against respiratory pathogens in swine. The controlled-release characteristics result from the unique crystalline structure and particle size distribution engineered into the formulation, providing reliable pharmacokinetic performance that supports single-dose therapeutic protocols.

Regulatory approval for ceftiofur crystalline free acid covers specific indications in cattle and swine, with particular emphasis on the extended-release properties that enable single-injection treatment of susceptible infections. The drug requires veterinary prescription and use within an established veterinarian-client-patient relationship. As a third-generation cephalosporin classified as critically important for human medicine, responsible use following labeled protocols and antimicrobial stewardship principles protects both animal welfare and public health. Proper administration technique, accurate dosing, and withdrawal time compliance remain essential for safe and effective use of this valuable therapeutic tool.

Bovine respiratory disease (BRD) represents the primary approved indication for ceftiofur crystalline free acid in cattle, addressing one of the most economically significant health challenges in beef production. The drug demonstrates excellent activity against major BRD-associated pathogens including Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. The extended-release formulation is particularly valuable for treating newly arrived feedlot cattle during high-risk receiving periods when daily handling for repeated treatments would add stress to animals already compromised by transportation and environmental changes. A single injection provides effective therapy for the typical duration of acute bacterial pneumonia.

Interdigital necrobacillosis, commonly known as foot rot, is an approved indication reflecting the drug's activity against Fusobacterium necrophorum and associated anaerobic pathogens. This painful condition causes significant lameness and production losses in beef and dairy cattle. The extended-release formulation offers practical advantages for treating foot rot, as a single injection provides sustained antimicrobial concentrations throughout the typical healing period. This reduces the need to re-catch and restrain animals for follow-up treatments, minimizing both labor requirements and additional stress to affected cattle recovering from this debilitating condition.

Acute bovine metritis in postpartum dairy and beef cattle represents another approved therapeutic indication. Uterine infections following calving involve pathogens including Escherichia coli, Fusobacterium necrophorum, and Trueperella pyogenes against which ceftiofur demonstrates activity. The systemic distribution of ceftiofur following subcutaneous administration achieves effective concentrations in uterine tissues. Extended-release characteristics provide sustained therapeutic levels during the acute infection phase, supporting resolution without repeated daily treatments that would require additional animal handling during the postpartum recovery period.

Swine respiratory disease associated with susceptible organisms constitutes the approved indication in pig production. Actinobacillus pleuropneumoniae causes severe acute pneumonia with high mortality, while Pasteurella multocida contributes to respiratory disease complex in growing pigs. Streptococcus suis and Haemophilus parasuis cause additional respiratory and systemic infections amenable to ceftiofur therapy. The extended-release formulation simplifies treatment logistics in swine operations where repeated individual animal treatment can be challenging, particularly in larger groups or continuous-flow production systems.

Control of respiratory disease in high-risk cattle populations represents an additional labeled use that extends beyond treatment to metaphylactic application. Cattle at elevated risk for BRD, such as those recently transported, commingled from multiple sources, or exposed to stressful conditions, may receive ceftiofur crystalline free acid as a single injection to prevent clinical disease development. This metaphylactic use must be implemented under veterinary supervision with appropriate diagnosis of disease risk in the population. Such preventive applications demonstrate value in high-risk scenarios but require judicious use to maintain antimicrobial stewardship standards.

Dosing of ceftiofur crystalline free acid in cattle follows a standardized protocol leveraging the extended-release formulation characteristics. The approved dose is 6.6 mg ceftiofur equivalents per kg body weight administered as a single subcutaneous injection at the base of the ear. This anatomical site is specifically designated because tissue at the ear base is removed during slaughter processing, eliminating concerns about injection site residues in edible carcass portions. A single dose provides therapeutic concentrations for approximately 7 days, sufficient for treating acute bacterial respiratory infections, foot rot, or metritis in most cases. A second dose may be administered 72 hours after the first if clinical signs persist or worsen.

Swine dosing protocols differ from cattle, reflecting species-specific pharmacokinetics and approved indications. The approved dose for swine respiratory disease is 5.0 mg ceftiofur equivalents per kg body weight administered as a single injection in the post-auricular region (behind the ear). This dose provides effective concentrations against susceptible respiratory pathogens for the treatment period. As with cattle, the injection site behind the ear is removed during processing, addressing carcass quality considerations. Accurate weight estimation is essential for achieving therapeutic doses, particularly in operations where pigs are treated in groups.

Injection technique significantly impacts both efficacy and safety of ceftiofur crystalline free acid administration. Subcutaneous injection at the ear base in cattle requires proper needle placement in the loose subcutaneous tissue of this region. Using an appropriately sized needle (16-18 gauge, 3/4 to 1 inch length) and inserting at a 45-degree angle ensures correct tissue deposition. The formulation is a thick suspension requiring adequate needle gauge for smooth injection. Injection volumes exceeding 15 mL in cattle should be divided between both ear bases to prevent excessive local tissue distension.

Proper handling of the product before administration ensures consistent dosing and formulation integrity. The bottle should be shaken vigorously before each use to resuspend the crystalline particles uniformly throughout the vehicle. Failure to shake adequately may result in inconsistent drug concentration between doses. The product should not be mixed with other medications in the same syringe. Using clean equipment and maintaining aseptic technique during preparation and administration reduces contamination risk and supports optimal therapeutic outcomes.

Calculating accurate doses requires reliable body weight estimation, particularly important given the concentrated nature of this extended-release formulation. Cattle scale weights provide the most accurate basis for dose calculation. When scale weighing is impractical, consistent estimation methods using measuring tapes or visual assessment by experienced personnel help achieve therapeutic doses. Underdosing risks treatment failure and promotes resistance selection, while overdosing increases cost and potential adverse effect risk. Training personnel in weight estimation and dose calculation supports consistent therapeutic application.

Withdrawal times for ceftiofur crystalline free acid reflect the extended-release pharmacokinetics and require strict observance. The meat withdrawal for cattle is 13 days following the last treatment. For swine, the slaughter withdrawal is 14 days. These extended withdrawals compared to shorter-acting ceftiofur products result from the depot formation that sustains drug release over time. Animals must not be sent to slaughter until the full withdrawal period has elapsed. Extra-label use would require veterinary-established extended withdrawals, though such use is discouraged given the already extended nature of approved protocols. Ceftiofur crystalline free acid is not approved for use in lactating dairy cattle, avoiding milk residue concerns but limiting application in dairy operations.

Ceftiofur crystalline free acid demonstrates a favorable safety profile consistent with other cephalosporin antibiotics, with adverse effects occurring infrequently when the product is used according to label directions. The extended-release formulation creates a localized depot at the injection site that influences the adverse effect profile compared to rapidly-absorbed formulations. Understanding potential side effects supports appropriate animal monitoring and enables prompt response to any unexpected reactions. The overall benefit-risk relationship strongly favors therapeutic use for approved indications.

Injection site reactions represent the most commonly observed adverse effects with ceftiofur crystalline free acid. The formation of a drug depot at the base of the ear predictably causes localized tissue response including swelling, firmness, and occasionally discoloration. These reactions typically peak within the first few days following injection and gradually resolve over 2-3 weeks. The ear base location is specifically selected because this tissue is removed during slaughter processing, rendering injection site reactions inconsequential for carcass quality. Visual changes at the injection site should not be confused with treatment failure or infection.

Mild transient swelling of ear tissues adjacent to the injection site may occur in some cattle. This edema typically resolves without intervention within several days. Severe or progressive swelling is uncommon and should prompt veterinary evaluation to distinguish expected drug reaction from infection or other complications. In swine, similar localized reactions occur at the post-auricular injection site, generally resolving within the expected timeframe without affecting the pig's overall health status or production performance.

Systemic adverse effects are uncommon with ceftiofur crystalline free acid at labeled doses. Hypersensitivity reactions can occur in animals with allergies to beta-lactam antibiotics, though such reactions are rare in food animal populations. Clinical signs may include urticaria, facial swelling, respiratory distress, or anaphylaxis in severe cases. Animals with documented previous reactions to penicillins or cephalosporins should not receive this medication. Emergency supplies including epinephrine should be available during treatment of animals with uncertain allergy history.

Gastrointestinal effects including mild diarrhea or decreased feed intake occur occasionally following treatment. These effects typically reflect transient disruption of normal intestinal microflora rather than direct drug toxicity and resolve following the treatment period. Severe or bloody diarrhea is uncommon and warrants veterinary investigation. The localized depot delivery of extended-release ceftiofur may actually reduce gastrointestinal impact compared to frequent dosing with conventional formulations by avoiding repeated peak drug concentrations. Most animals maintain normal appetite and behavior throughout the treatment period.

Ceftiofur crystalline free acid is contraindicated in animals with known hypersensitivity to cephalosporin antibiotics or penicillins. Cross-allergenicity between these beta-lactam antibiotic classes means animals with documented penicillin allergy face elevated risk of reactions to cephalosporins. Previous anaphylactic reactions to any beta-lactam antibiotic absolutely preclude use of ceftiofur crystalline free acid. Obtaining treatment history when available helps identify at-risk animals. When allergy status is uncertain and treatment urgency exists, having epinephrine immediately available provides a safety measure for managing unexpected reactions.

The product is not approved for use in lactating dairy cattle, representing a significant use restriction. This contraindication reflects the lack of established milk withdrawal data and the extended-release characteristics that would require prolonged milk discard if the drug were used in dairy cattle producing milk for human consumption. Dairy operations must use alternative ceftiofur formulations with established milk withdrawal times when treating lactating cattle. Dry dairy cattle may receive the product if slaughter withdrawal can be observed before any future lactation, though practical considerations often favor other treatment options in dairy settings.

Proximity to slaughter creates practical limitations on ceftiofur crystalline free acid use. The 13-day meat withdrawal in cattle and 14-day withdrawal in swine means animals anticipated to go to slaughter within these timeframes should not receive treatment, as compliance with withdrawal requirements would delay marketing. Animals receiving treatment must be clearly identified and segregated as needed to ensure withdrawal completion before slaughter. Operations must maintain accurate treatment records supporting withdrawal compliance for regulatory inspection.

Administration at locations other than the approved injection sites is contraindicated and constitutes extra-label use. The ear base in cattle and post-auricular region in swine represent the only approved administration sites, selected specifically because these tissues are removed during slaughter processing. Injection into neck, shoulder, or hindquarter locations would create potential for injection site lesions in marketed carcasses and would require extended withdrawal periods beyond the labeled 13 or 14 days. Maintaining injection site discipline protects both carcass quality and ensures appropriate withdrawal time application.

Ceftiofur crystalline free acid exhibits relatively few clinically significant drug interactions, though awareness of potential interactions supports optimal therapeutic decision-making. Bacteriostatic antibiotics including tetracyclines, macrolides, and phenicols may theoretically antagonize the bactericidal activity of ceftiofur by inhibiting bacterial protein synthesis and cell division. Since beta-lactam antibiotics require actively dividing bacteria for optimal effect, concurrent bacteriostatic therapy could reduce efficacy. Simultaneous administration of bacteriostatic and bactericidal antibiotics should generally be avoided unless specifically indicated by established treatment protocols or veterinary judgment in complex cases.

Combining ceftiofur crystalline free acid with other injectable antibiotics administered at the same time creates complexity without established benefit for most situations. The extended-release characteristics of ceftiofur crystalline free acid provide sustained antimicrobial activity, reducing the rationale for concurrent antibiotic administration. If treatment failure occurs or additional coverage is needed, sequential therapy with alternative agents following the ceftiofur treatment period represents a more rational approach than simultaneous multi-drug regimens. Veterinary consultation helps determine appropriate therapy escalation when initial treatment response is inadequate.

Aminoglycoside antibiotics combined with cephalosporins can provide synergistic bactericidal activity against certain pathogens, though this combination is less commonly implemented with extended-release formulations. If aminoglycoside therapy is indicated based on culture and sensitivity results or clinical circumstances, administration should occur at separate times and sites from ceftiofur crystalline free acid. Physical mixing of these drugs is contraindicated due to chemical incompatibility. The decision to combine antibiotic classes should reflect clear therapeutic rationale and occur under veterinary supervision.

Non-steroidal anti-inflammatory drugs are frequently co-administered with antibiotics for treating bovine respiratory disease, combining antimicrobial therapy with fever reduction and anti-inflammatory effects. This combination is generally well-tolerated, with no significant pharmacokinetic interactions between ceftiofur and NSAIDs documented. Flunixin meglumine, meloxicam, and other approved NSAIDs may be administered concurrently with ceftiofur crystalline free acid according to their respective labels. Maintaining appropriate withdrawal times for all administered drugs is essential when multiple treatments are given.

Human safety precautions during handling and administration of ceftiofur crystalline free acid protect personnel from potential occupational hazards. Individuals with known allergies to beta-lactam antibiotics should not handle the product, as skin contact may cause sensitization or trigger allergic reactions. Gloves should be worn during product preparation and administration. Accidental self-injection requires immediate medical attention, with the product package or insert provided to healthcare personnel for identification of the administered drug. Washing hands after handling and avoiding contact with eyes or mucous membranes represents standard precautionary practice.

Food safety compliance demands strict adherence to withdrawal times and accurate treatment record-keeping. The 13-day cattle and 14-day swine slaughter withdrawals must be fully observed before treated animals enter the food supply. Treatment records should include animal identification, product name, dose, date of treatment, and calculated withdrawal date. Mixing treated and untreated animals without proper identification risks inadvertent marketing of animals with violative residues. Bulk commodity operations must have systems ensuring no treated animals go to slaughter before withdrawal completion.

Proper injection site selection protects both food safety and animal welfare. Administration only at the base of the ear in cattle or post-auricular region in swine ensures injection site tissue is removed during processing, eliminating carcass quality concerns from expected local reactions. These specific sites also provide accessible, consistent injection locations that support accurate subcutaneous drug deposition. Personnel should be trained in proper technique including needle size selection, insertion angle, and injection volume limits to optimize therapeutic outcomes.

Antimicrobial stewardship responsibilities apply particularly to third-generation cephalosporins given their classification as critically important antimicrobials. Use should be limited to situations with appropriate indications and reasonable expectation of susceptible pathogens. When practical, culture and sensitivity testing should guide therapy decisions. Metaphylactic use for disease control requires veterinary oversight with documented disease risk assessment. Completing appropriate treatment protocols, maintaining accurate records, and reporting treatment outcomes supports responsible use that protects antimicrobial effectiveness for future needs.

Resistance prevention requires attention to dosing accuracy and treatment protocol compliance. The extended-release formulation is engineered to maintain therapeutic concentrations, but underdosing due to inaccurate weight estimation undermines this benefit and promotes resistance selection. Using proper restraint, appropriate dosing equipment, and verified weight estimation methods supports consistent therapeutic dosing. Monitoring treatment outcomes helps identify potential resistance emergence requiring alternative therapy approaches or diagnostic investigation.

Storage of ceftiofur crystalline free acid requires protection from temperature extremes to maintain product integrity and therapeutic effectiveness. The product should be stored at controlled room temperature between 20-25°C (68-77°F), with protection from freezing. Freezing may permanently damage the suspension characteristics and crystalline structure essential for extended-release performance. Excessive heat exposure should similarly be avoided. Storage in temperature-controlled medication rooms or appropriate facilities in farm settings supports product stability throughout the labeled shelf life.

Proper preparation before administration ensures consistent dosing and formulation performance. The bottle must be shaken vigorously before each withdrawal to uniformly suspend the crystalline particles throughout the vehicle. Inadequate shaking results in inconsistent drug concentration between doses, potentially causing underdosing or overdosing. The viscous nature of the suspension requires brief delay after shaking to allow air bubbles to rise before drawing the dose. Visual inspection should confirm uniform appearance without separation or particulate clumping.

Multi-dose vial handling follows standard aseptic practices. Wiping the rubber stopper with alcohol before each needle entry minimizes contamination risk. Using clean needles for each withdrawal prevents potential cross-contamination between the product and injection equipment. Recording the date of first use on the vial label supports tracking product age. The product should be used within the labeled period following initial entry, typically 12 weeks, regardless of remaining volume. Any visible changes in appearance, including color change, unusual particulate matter, or failure to resuspend properly, indicate the product should be discarded.

Disposal of unused or expired ceftiofur crystalline free acid requires appropriate handling to prevent environmental contamination. The product should not be disposed of through regular trash or poured into drains or water systems. Pharmaceutical take-back programs or approved disposal services provide appropriate channels where available. Empty containers should be triple-rinsed and disposed of according to label directions. Proper disposal practices protect environmental quality and prevent contribution to antimicrobial resistance selection in environmental bacterial populations.

Species-specific considerations for ceftiofur crystalline free acid primarily distinguish cattle and swine applications, as these represent the two approved target species. Cattle of all production types may receive the product according to labeled protocols, though the exclusion of lactating dairy cattle from approved indications limits dairy applications. Beef cattle in feedlot, pasture, or backgrounding operations represent the primary use population, particularly for bovine respiratory disease treatment and prevention during high-risk receiving periods. Cow-calf operations may use the product for treating respiratory disease, foot rot, or metritis in beef breeding stock.

Breed-specific drug response variations are not well-documented for ceftiofur crystalline free acid, with the formulation demonstrating consistent pharmacokinetic performance across diverse cattle breeds tested during product development. Continental European breeds, British breeds, dairy breeds, and crossbred cattle all respond to standardized dosing protocols. Individual animal variation in drug handling exists within any population, but breed-specific dose adjustments are not typically required. Accurate weight-based dosing remains the primary determinant of therapeutic success regardless of breed.

Swine breed and genetic line considerations similarly show no documented variations requiring dose modification from labeled recommendations. Modern commercial pig genotypes including those from various genetic suppliers receive standard dosing. Heritage or specialty breeds without extensive pharmacokinetic data may be treated following labeled protocols with veterinary oversight. The 5.0 mg/kg dose provides consistent therapeutic effect across the range of swine types encountered in commercial production.

Age and production stage influence ceftiofur crystalline free acid application beyond species and breed considerations. Young cattle during the high-risk period following weaning and transport represent a common treatment population. Mature breeding animals with respiratory or reproductive infections may receive treatment following standard protocols. The extended-release characteristics simplify treatment logistics across age groups by eliminating repeated handling requirements. Swine applications similarly span ages from growing pigs through breeding stock, with weight-based dosing providing the framework for appropriate treatment across production stages.

Conventional ceftiofur formulations including ceftiofur hydrochloride (Excenel RTU, Naxcel) and ceftiofur sodium provide shorter-acting alternatives requiring daily administration. These products offer flexibility for situations where extended-release characteristics are not advantageous or where conditions require more frequent monitoring and potential therapy adjustment. The active metabolite and antimicrobial spectrum are identical to ceftiofur crystalline free acid, with formulation differences determining duration of action and administration frequency. Selection between extended-release and conventional formulations depends on specific clinical circumstances, handling logistics, and treatment goals.

Other third-generation cephalosporins used in human or companion animal medicine share similar broad-spectrum activity but are not approved for food animal use. Ceftiofur remains unique among veterinary cephalosporins for its specific development targeting food animal species with associated residue avoidance data. Using non-approved cephalosporins would constitute extra-label drug use with unknown withdrawal times and significant regulatory risk. Veterinarians requiring cephalosporin therapy in food animals should utilize approved ceftiofur products with established safety and residue data.

Alternative beta-lactam antibiotics including penicillins provide options for situations where cephalosporins are unavailable, contraindicated, or where narrower spectrum therapy is preferred. Ampicillin and amoxicillin offer aminopenicillin activity against gram-negative organisms, though beta-lactamase-producing strains show resistance. Penicillin G preparations target gram-positive pathogens effectively. These alternatives typically require more frequent dosing than extended-release ceftiofur but may be appropriate for specific infections or stewardship considerations favoring narrower-spectrum initial therapy with escalation if needed.